China is a growing biotech player whose main competitive edge lies in low development costs. But will inexperienced money men and a disinterested pharmaceutical industry hold it back? Sabine Louët investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
01 January 2005
Nat. Biotechnol. 22, 1497–1499 (2004) On page 1497, col. 2, paragraph 2, the names of a Shanghai consultancy and its CEO were misspelled. The name of the company is General Biologic and the CEO's name is Matt Chervenak.
References
General Biologic. “China Pipeline 2004” (General Biologic, Shanghai, China, 2004) (http://www.generalbiologic.com/).
Anscomb, A. Pharmaceutical outsourcing opportunities post launch. in Kalorama Information Market Intelligence (ed. Heffner, S.) (Kalorama Information, New York, 2004).
Basu, P. Nat. Biotechnol., 22, 263–265, 2004.
Pearson, S., Jia, H. & Kandachi, K. Nat. Biotechnol. 22, 3–4, 2004.
Jia, H. Nat. Biotechnol. 22, 368, 2004.
Liu, J.L. BioEntrepreneur 6 November 2003 (doi: 10.1038/bioent778).
Liu, J.L. Bioentrepreneur 23 October 2003 (doi:10.1038/bioent776).
McNeil, D.G. New York Times, May 14 (2004).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Louët, S. Can China bring its own pipeline to the market?. Nat Biotechnol 22, 1497–1499 (2004). https://doi.org/10.1038/nbt1204-1497
Issue Date:
DOI: https://doi.org/10.1038/nbt1204-1497
This article is cited by
-
The drug lag issue: a 20-year review of China
Investigational New Drugs (2021)
-
Chinese health biotech and the billion-patient market
Nature Biotechnology (2008)
-
China offers alternative gateway for experimental drugs
Nature Biotechnology (2006)
-
Consenting adults? Not necessarily...
Nature (2005)
-
Erratum: Can China bring its own pipeline to the market?
Nature Biotechnology (2005)